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Abstract
Acute myeloid leukemia (AML) is a clonal disease originating from myeloid progenitor cells with a heterogeneous genetic
background. High-dose cytarabine is used as the standard consolidation chemotherapy. Oncogenic RAS mutations are
frequently observed in AML, and are associated with beneficial response to cytarabine. Why AML-patients with oncogenic
RAS benefit most from high-dose cytarabine post-remission therapy is not well understood. Here we used bone marrow
cells expressing a conditional MLL-ENL-ER oncogene to investigate the interaction of oncogenic RAS and chemotherapeutic
agents. We show that oncogenic RAS synergizes with cytotoxic agents such as cytarabine in activation of DNA damage
checkpoints, resulting in a p53-dependent genetic program that reduces clonogenicity and increases myeloid
differentiation. Our data can explain the beneficial effects observed for AML patients with oncogenic RAS treated with
higher dosages of cytarabine and suggest that induction of p53-dependent differentiation, e.g. by interfering with Mdm2-
mediated degradation, may be a rational approach to increase cure rate in response to chemotherapy. The data also
support the notion that the therapeutic success of cytotoxic drugs may depend on their ability to promote the
differentiation of tumor-initiating cells.
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Introduction
Acute myeloid leukemia (AML) is a clonal disease with a
heterogeneous genetic background. Besides age, cytogenetic
alterations and molecular lesions such as mutations in the FLT-3
or nucleophosmin genes play a pivotal role in predicting treatment
response ([1]; reviewed in [2,3]). AML is treated with induction
and post-remission chemotherapy, frequently including high-dose
cytarabine [4]; reviewed in: [5]. Mutations in NRAS and KRAS
protooncogenes (resulting in ‘‘oncogenic’’ RAS) occur in approx-
imately 20% of AML cases (reviewed in: [6]).
It has been suggested that leukemic transformation depends on
the occurrence of two genetic lesions in a susceptible progenitor
cell. Class I mutations that affect genes encoding receptor tyrosine
kinases (Flt-3 or Kit) or RAS are thought to induce myeloid
proliferation. Class II lesions affect transcription factors such as
nucleophosmin, C/EBPa, AML-ETO, MLL-ENL, PML-RARa
and block differentiation (e.g. [7]; reviewed in: [3]). Supporting
this notion, oncogenic RAS alone induces a myeloproliferative state
in murine models [8–12] and in cooperation with nuclear
oncogenes such as PML-RARa induces acute leukemia [13].
Oncogenic RAS can also promote the differentiation of hemato-
poietic and other cells [14–18]. In non-hematopoietic cells such as
primary fibroblasts, oncogenic RAS induces a permanent growth
arrest termed senescence, which limits RAS-induced tumorigenesis in
vivo [19–23]. Induction of senescence by oncogenic RAS involves
activation of DNA damage checkpoints and is mediated by p53
[24,25]. Therefore, in presence of functional p53 oncogenic RAS
activates a ‘‘fail-safe’’ mechanism, which protects from RAS-induced
malignant transformation.
A previous landmark study showed that AML patients benefit
from high-dose cytarabine as post-induction therapy, which has
subsequently become the standard consolidation therapy in AML
[4]. Using AML samples taken from this study, we have previously
shown that AML patients harboring oncogenic RAS show
significantly less cumulative incidence of relapse upon treatment
with high-dose cytarabine in the post-induction chemotherapy
(best group), when compared to AML patients with oncogenic RAS
treated with low-dose cytarabine (worst group). In contrast, dose
escalation had a much weaker effect on the response to cytarabine
in patients that harbour wild type RAS (intermediate groups [26]).
These data suggested that there is a genetic interaction between
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Importantly, multivariate analysis revealed that the interaction of
RAS with cytarabine dose escalation was independent of cyto-
genetic status of the leukemic blasts, suggesting that oncogenic RAS
affects the response of AML blasts to cytarabine [26]. Moreover,
since the beneficial effect of high-dose cytarabine with oncogenic
RAS is observed especially in the post-induction therapy, the
findings suggested that the number of clonogenic leukemia-
initiating cells was reduced as the result of an interaction between
oncogenic RAS and cytarabine.
To better understand the interaction of RAS with cytarabine, we
expressed oncogenic RAS in primary mouse bone marrow stem
cells that had been immortalized by a MLL-ENL oncogene [27].
In this tissue-culture system, MLL-ENL acts as the class II
mutation, whereas supplementation of the medium with growth
factors presumably substitutes for a class I mutation. We find that
oncogenic RAS in combination with DNA-damaging agents such
as cytarabine decreases the clonogenic potential of these cells and
induces a myeloid differentiation program in a DNA damage
checkpoint- and p53-dependent manner. Our data suggest that in
AML patients with oncogenic RAS, high-dose cytarabine therapy
is effective since it promotes the differentiation of tumor-initiating
cells.
Results
Immortalized bone marrow stem cells expressing
oncogenic RAS do not show enhanced proliferation,
apoptosis or senescence in response to cytarabine
We infected mouse bone marrow cells that had been immor-
talized with a conditional MLL-ENL-ER oncogene [27] with
either control retroviruses (empty vector: ‘‘EV’’) or retroviruses
expressing an oncogenic Ha-RasV12 protein (generating EV and
Ras cells; Figure 1A). Immunoblots confirmed that Ras cells
expressed elevated levels of the Ha-Ras protein and displayed
activation of Ras proteins as determined by binding to a GST-Raf
protein and phosphorylation of Erk, a downstream effector of Ras
(Figure 1B). Expression of RAS did not significantly affect the
expression of MLL-ENL-ER (Figure S1) and of meis1 and hoxa9,
which are critical target genes of MLL-ENL [28] (Figure 1C).
Furthermore, withdrawing 4-hydroxy-tamoxifen (OHT) to switch
off the function of the MLL-ENL-ER chimera resulted in
differentiation of both control (EV) and Ras cells as shown by
the increased expression of markers of monocytic (itgam encoding
Mac 1) and granulocytic (ly6g encoding the Gr1 antigen) differ-
entiation (Figure 1D) and in downregulation of meis1 and hoxa9
expression (Figure 1C), demonstrating that oncogenic RAS did
Figure 1. Generation of MLL-ENL-ER cells expressing oncogenic Ha-RasV12. (A) Flow chart of the generation of MLL-ENL-ER cells infected
with either control retroviruses (empty vector; ‘‘EV cells’’) or retroviruses expressing oncogenic HA-RASV12 (generating Ras cells). (B) Elevated Ras
expression and activity upon infection of MLL-ENL-ER cells. Control and Ras cells were treated with 50 mM cytarabine for the indicated times. Cell
lysates were either incubated with GST-Raf bound to glutathione beads and immunoblots of bound proteins probed with pan-Ras antibody (‘‘active
Ras’’) or cells lysates were probed with antibodies against phosphorylated Erk (pTyr-204) and Ras. Cdk2 served as loading control in this panel and all
subsequent immunoblots. (C) MLL-ENL-ER target genes are not influenced by oncogenic RAS. Control and Ras cells were cultured for 12 days in the
presence or absence of 4-OHT. Expression of meis1 and hoxa9 was analysed by RQ-PCR. Each column represents the mean6SD in this panel and all
subsequent RQ-PCRs. The double asterisk represents statistical significance (p,0.01) of differences between cells cultured in the presence and
absence of 4-OHT, respectively. (D) Oncogenic RAS does not abrogate the differentiation due to withdrawal of 4-OHT. Control and Ras cells were
cultured for 12 days in the presence or absence of 4-OHT and the expression of the differentiation markers ly6g (encoding Gr1) and itgam (encoding
Mac1) was measured by RQ-PCR. Statistical significance refers to differences between cells cultured in the presence or absence of 4-OHT, respectively.
doi:10.1371/journal.pone.0007768.g001
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MLL-ENL-ER.
Treatment with cytarabine (AraC) had no significant effect on
expression of total or active Ras in either control or Ras cells
(Figure 1B). In response to treatment with either low (10 nM) or
elevated (100 nM) concentrations of cytarabine, both control and
Ras cells showed a comparable decrease in cell number (Figure 2A).
Furthermore, cytarabine inhibited DNA replication in both cell
types to a similar extent, as measured by BrdU incorporation in a
two-dimensional FACS analysis (Figure 2B). This analysis also
showed that both cell types underwent apoptosis in response
to either a transient (three hour pulse) or prolonged treatment
(24 hours) with cytarabine (detected as cells with a subG1 DNA
content in Figure 2B). Addition of cytarabine led to an increase in
expression of two marker genes of senescence, ink4b and dec-1 [29],
in both control and Ras cells; possibly, therefore, cytarabine can
induce senescence in MLL-ENL cells (Figure 2C). However, the
cells were only weakly positive for a second marker of senescence,
acidic b-galactosidase, and this was not affected by cytarabine
(Figure 2D), suggesting that induction of senescence does not
account for the selective loss of clonogenicity observed in Ras cells
(see below).
Ras cells show reduced colony formation potential and
enhanced checkpoint activation after treatment with
cytarabine
We next tested the ability of control and Ras cells to form
colonies in semisolid medium after treatment with cytarabine.
Cells were pre-treated in suspension for 24 hours with cytarabine
at different concentrations, then plated in semisolid medium in the
absence of the drug. Colony formation was scored after four days.
No apparent difference was found between the two cell types in
the absence or in the presence of lower doses of cytarabine
(10 nM) (Figure 2E); pre-incubation with a higher concentration of
100 nM cytarabine led to a moderate (3.5fold) decrease in the
colony forming capacity of control cells; in contrast, the same
treatment largely abolished the clonogenic potential of Ras cells
(Figures 2E,F). Thus, transient exposure to cytarabine reduces the
clonogenic potential of Ras cells more strongly than that of control
cells (Figure S2A). Slightly elevated concentrations of cytarabine
were required to suppress colony formation in a second,
independently derived clone of MLL-ENL cells (Figure S2B).
Importantly, expression of RAS also enhanced the sensitivity to
cytarabine in these cells, confirming that the difference in
sensitivity was due to expression of RAS and not due to variations
during the infection and selection of cells in culture (Figure S2B).
Since we observed no difference between control and Ras cells
in the total level of apoptosis or senescence upon exposure to
cytarabine, we considered two mutually non-exclusive possibilities
to account for the differences observed in the clonogenic assays:
First, MLL-ENL and Ras cells – despite being clonal isolates –
might be heterogeneous with respect to clonogenic potential.
Therefore, the response to cytarabine that is measured in the total
cell pool may be determined by the majority of non-clonogenic
cells and may not reflect the response of a potentially small pool of
clonogenic cells; consistent with these suggestion, we observed that
only a fraction of both cell types expressed the monocyte/
macrophage marker Mac1 or c-kit, which is a marker of stem and
progenitor cells (Figures S3A,B) and that the clonogenic
population of both control and Ras cells could be enriched by
isolating either a Mac1-depleted or a c-kit-enriched population
(Figure S3C). Therefore, in both control and Ras cells, the cells
enriched for a more immature phentype revealed similar colony
forming capacity, arguing that they did not express a qualitative
difference with regard to colony formation. Second, the clonogenic
potential might be reduced by a process that is distinct from both
apoptosis or senescence; this possibility was addressed in experi-
ments described further below.
To identify the mechanisms underlying the impaired clono-
genicity of Ras cells, we wondered whether either of two events
that occur in response to oncogenic activation of Ras could
account for this observation: first, oncogenic Ras induces the
expression of p16
Ink4a and p19
Arf, leading to increased levels of
p53, and p21
Cip1 [19,30]. Consistent with these observations, Ras
cells expressed elevated levels of p16
Ink4a and p19
Arf, and this was
independent of the exposure to the DNA-damaging agent
cytarabine; consequently, levels of p21
Cip1 and p53 were elevated
in Ras cells even in the absence of cytarabine (Figures 3A,B).
Second, oncogenic Ras can induce a DNA damage response in
primary cells, which leads to activation of the Atm and Atr
checkpoint kinases [24,25,31]. We did not observe elevated levels
of phosphorylated Chk1 or H2a.x, which are targets of the Atm or
Atr kinases in immunoblots of either control or Ras cells before
treatment with cytarabine (Figures 3C,D); furthermore, immuno-
fluorescence did not reveal a difference in phosphorylated Atm in
untreated cells (Figure 3E). However, cytarabine strongly induced
phosphorylation of Chk1 in Ras cells, whereas the phosphorylation
of this protein was hardly detectable in control cells treated with
cytarabine. Unphosphorylated Chk1 was not differentially ex-
pressed between control and Ras cells (Figure 3C). This difference
in checkpoint responses was not due to a reduced rate of DNA
replication in control cells, which would lead to a reduced
incorporation of cytarabine (Figure 2B). Ras cells also displayed
strongly elevated levels of phosphorylated H2a.x and Atm after
incubation with cytarabine relative to control cells (Figures 3D,E).
Consistent with these observations, exposure to cytarabine led to a
further increase in levels of p21
Cip1 in Ras cells, whereas induction
of p21
Cip1 was hardly detectable in control cells (Figure 3A). The
data show that oncogenic RAS cooperates with cytarabine in
activation of DNA damage-dependent checkpoints.
Both mutation and enhanced expression of RAS genes have
been reported in AML [32]. To determine whether elevation of
checkpoint responses is specific for oncogenic Ras or whether it
reflects the elevated levels of total Ras present in Ras cells, we
determined the level of Chk1 phosphorylation in two pools of
MLL-ENL cells that had been infected with retroviruses
expressing wild type Ha-RAS (Figure S4). Enhanced phosphory-
lation of Chk1 was observed in cells expressing mutated RAS, but
also – albeit to a significantly lesser extend - in cells expressing
high-levels of wild type RAS. Most likely, therefore, both, the
oncogenic mutation of RAS and - more weakly – the enhanced
expression contribute to the altered checkpoint activity of Ras cells.
DNA-damaging agents such as daunorubicine and
etoposide also reveal differential effects in Ras cells
In order to elucidate if the observed effects on DNA-damage
checkpoints and the impaired capacity to form colonies in vitro
were specific for cytarabine, we investigated the effects of the
topoisomerase II inhibitors daunorubicine and etoposide on
colony formation and DNA-damage checkpoints in control and
Ras cells and compared this to cytarabine. Both control and Ras
cells showed a dose-dependent phosphorylation of Chk1
(Figure 4A) and inhibition of colony formation (Figure 4B) in
response to cytarabine. Consistent with our previous data, Ras cells
showed an enhanced checkpoint response at all cytarabine
concentrations tested (for a quantitation, see Figure S5A) and
were more sensitive with respect to colony formation (Figure S5B)
at elevated concentrations of cytarabine. Similarly, when control
RAS and Cytarabine in AML
PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7768Figure 2. Oncogenic RAS compromises clonogenicity upon treatment with cytarabine. (A) Control and Ras cells show no difference in
viability upon cytarabine (AraC) treatment. Cells were treated with cytarabine for 24 hours as indicated and live cells were counted in triplicates using
exclusion of trypan blue as criterion. (B) Cytarabine has identical effects on replication and apoptosis of control and Ras cells, respectively. Control and
Ras cells were treated either for three hours with 10 mM cytarabine and subsequently cultured for 21 hours in the absence of cytarabine or
continuously treated for 24 hours. As a control, cells were cultured without drug. One hour before harvesting, BrdU was added to the culture. Cells
were stained with propidium iodide and a-BrdU-FITC antibodies and subjected to FACS analysis. (C) Cytarabine induces expression of senescence
markers ink4b and dec-1 in control and Ras cells. Cells were cultured with 350 nM cytarabine for the indicated times and expression was analysed by
RQ-PCR. At each time point statistical significance of differences between control cells and Ras cells was calculated. The asterisks in this panel and all
subsequent panels represent statistical significance at p,0.05 for single asterisk and p,0.01 for double asterisk. (D) Senescence associated acidic
b-galactosidase staining reveals no difference between control and Ras cells. Cells were treated with 350 nM cytarabine for 24 hours, then cultured
for additional 48 hours in the absence of cytarabine and subjected to an acidic b-galactosidase assay. (E) Ras cells show compromised colony
formation upon cytarabine treatment. Control and Ras cells were treated for 24 hours either with 10 nM or 100 nM cytarabine as indicated. Samples
of 3.000 cells each were plated in methylcellulose. Colonies were stained after four days. (F) Quantification of (E). The graph shows the number of
colonies relative to the number of colonies observed in the absence of cytarabine. The graph shows the average of three independent experiments.
doi:10.1371/journal.pone.0007768.g002
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cells appeared more sensitive towards incubation with these drugs
with regard to phosphorylation of Chk1 and colony formation,
respectively (Figures 4C and D: daunorubicine; 4E and F:
etoposide). Thus, the differential response of Ras vs. control cells
was not only seen after treatment with cytarabine, but also with
daunorubicine and etoposide.
Oncogenic RAS induces myeloid differentiation after
cytarabine treatment
We next asked whether the selective loss of clonogenic potential
of Ras cells in response to cytarabine correlates with an increase in
differentiation [14–18,33]. Control and Ras cells were incubated
with cytarabine, and differentiation was determined by analyzing
cellular morphology and the expression of markers of granulocytic
(Gr1) and monocytic differentiation (Mac1). There was a significant
enhancement of differentiation in cells expressing oncogenic RAS
after treatment with cytarabine as observed in May-Grunwald-
Giemsa-stained slides (Figure 5A and Figure S6A) as well as in
RQ-PCRand FACSanalysesofly6g(encodingthe Gr1antigen)and
itgam (encoding Mac 1) (Figure 5B and Figure S6B). Consistent with
these observations, the mRNA levels of the stem cell marker kit were
lower in Ras cells and expression became virtually undetectable
upon treatment with cytarabine (Figure 5C).
To test whether the enhanced differentiation observed in Ras
cells depends on the elevated checkpoint activity in response to
cytarabine, we incubated control and Ras cells for 24 hours with
cytarabine in the presence or absence of caffeine, an inhibitor of
the Atm and Atr kinases [34]. Initial experiments showed that
incubation with 0.5 mM caffeine was sufficient to inhibit phos-
phorylation and thus activation of Chk1, as demonstrated by the
reduced level of p53 (Figure S7A+B). Notably, treatment with
caffeine together with cytarabine markedly decreased the myeloid
differentiation of Ras cells (Figure 5D). In contrast, addition of
Figure 3. Ras cells express elevated levels of p16
Ink4a and p19
Arf and show increased checkpoint activity. (A) Immunoblot documenting
the elevated basal expression and further induction of p21
Cip1 after cytarabine treatment and increased expression of p16
Ink4a and p19
Arf in Ras cells.
Control and Ras cells were treated with 350 nM cytarabine for the indicated times and cell lysates were probed with the indicated antibodies. Cdk2 is
shown as loading control. (B) Ras cells express elevated levels of p53. Control and Ras cells were either treated with 100 mM cytarabine for five hours
or exposed to UVB for 3.5 min and subsequently incubated for five additional hours. Immunoblots of cell lysates were probed with antibodies against
p53 and Cdk2 as shown. (C) Phosphorylation of Chk1 is increased in Ras cells after treatment with cytarabine. Control and Ras cells were treated with
100 mM cytarabine for the indicated times. The panels show immunoblots of cell lysates subjected to antibodies against Chk1 and phospho-Chk1
(pSer345). (D/E) Ras cells show elevated checkpoint activation upon cytarabine treatment. Control and Ras cells were treated as before. Panel D
shows immunoblots of cell lysates that were probed with antibodies directed against phospho-H2a.x (pSer139) and Cdk2 (loading control). Panel E
shows immunofluorescence pictures of control and Ras cells treated with 100 mM cytarabine for one hour and stained with antibodies directed
against phosphorylated Atm (pSer1981) (green). DNA was counterstained with Hoechst (blue).
doi:10.1371/journal.pone.0007768.g003
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with cytarabine, potentially because caffeine showed significant
toxicity in long-term experiments (not shown). Taken together, the
data show that the cytarabine-induced loss of clonogenicity corre-
lates with a checkpoint-dependent induction of cellular differenti-
ation of Ras cells.
Importantly, inducing cellular differentiation by withdrawal of
4-hydroxy-tamoxifen and subsequent inactivation of the MLL-
ENL-ER chimeric protein did not elevate checkpoint activation in
the absence of oncogenic RAS (Figure S8), suggesting that the
effects of oncogenic Ras on checkpoint activity are upstream and
independent of its effects on cellular differentiation.
Figures 5B and C show a higher spontaneous differentiation of
Ras cells, even without in vitro treatment with cytarabine. In order
to investigate if oncogenic Ras induced myeloid differentiation,
which is potentiated by activating DNA-damaging agents such as
cytarabine, may also be observed in primary AML, we analyzed
primary AML samples using cDNA expression analysis. We took
advantage of primary AML cases diagnosed within the AML-SHG
Germany multicenter study group and selected 31 AML cases with
inversion (16) to have a comparable genetic background. AML
with oncogenic N-RAS mutations (N=12) revealed a different
expression signature as compared to AML lacking such mutations
(N=19). A Gene Set Enrichment Analysis demonstrated that
genes characteristic for hematopoietic progenitors were expressed
at higher levels in samples harbouring wild-type N-RAS while
genes associated with mature blood cells rather than progenitor
and stem cell compartments were strongly enriched (up-regulated)
in the N-RAS mutant samples (not shown) [35,36]. We confirmed
the more differentiated phenotype of N-RAS mutant AML using
RQ-PCR for the SIAT10 gene, which is known to be progressively
up-regulated during myeloid differentiation (Figure 5E) [35]. The
higher spontaneous differentiation observed for Ras cells in vitro
was therefore also detected in primary AML samples.
Figure 4. Ras cells show elevated checkpoint activity in response to treatment with cytarabine, daunorubicine or etoposide. (A)
Phosphorylation of Chk1 in response to cytarabine treatment is dose-dependent and elevated in Ras cells. Control and Ras cells were treated with
350 nM, 1 mM, 10 mM, 50 mM and 100 mM cytarabine for 1 hour and analyzed by immunoblot probing for phospho-Chk1 (pSer345) and Cdk2. (B)
Control and Ras cells show dose-dependent decrease of colony formation upon cytarabine treatment. Samples of 3.000 cells each were plated in
methylcellulose. Shown is the average number of colonies observed in three independent assays as percentage of colonies observed in control
incubation in the absence of cytarabine. Ras cells show significantly fewer colonies compared to control cells (85 nM, 150 nM: p,0.05; 100 nM,
125 nM: p,0.01). (C) Daunorubicine leads to enhanced phosphorylation of Chk1 in Ras cells. The immunoblot shows lysates of cells, which were
treated with 1 mM, 10 mM and 50 mM daunorubicine for 1 hour and probed as before. (D) Ras cells treated with daunorubicine show compromised
colony formation. Control and Ras cells were incubated for 24 hours with the indicated concentrations of daunorubicine. 3.000 cells each were plated
in methylcellulose and stained after four days. The graph shows the average number of colonies observed in three independent experiments relative
to the number of colonies observed in the absence of drug. Statistical significance refers to differences between the colony formation of control cells
and Ras cells. (E) Ras cells are more sensitive in checkpoint activation towards etoposide treatment. Cells were treated with 1 mM, 10 mM and 50 mM
etoposide for 1 hour and lysates were analysed by immunoblot using the same antibodies as before. (F) Etoposide has a stronger effect on the
colony formation of Ras cells. Control- and Ras cells were either untreated or treated with 50 nM and 250 nM etoposide for 24 hours, respectively,
before 3.000 cells each were plated in methylcellulose. The graph shows the average number of colonies observed in three independent experiments
relative to the number of colonies observed in the absence of drug.
doi:10.1371/journal.pone.0007768.g004
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PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7768Figure 5. Ras cells show myeloid differentiation upon cytarabine treatment. (A) Morphological analysis reveals differentiation of Ras cells.
Control and Ras cells were treated with 350 nM cytarabine for 24 hours. Cells were washed and cultured for additional 48 hours in the absence of
cytarabine and stained with May-Grunwald/Giemsa. Untreated control and Ras cells have a similar blastic phenotype. Treatment with cytarabine
induces a modest differentiation in control cells; this is potentiated in Ras cells. Shown is a representative experiment. Specific differential counts of
these cells is presented in Figure S6A. (B) Upper panels: Elevated expression of markers of differentiation in Ras cells. Control and Ras cells were
cultured with 350 nM cytarabine for the indicated times and ly6g and itgam mRNAs were analysed by RQ-PCR. The asterisk represents statistical
significance of differences between control- and Ras cells at the indicated time points. Lower panel: Gr1 protein expression is elevated in Ras cells.
Control and Ras cells were treated with 350 nM cytarabine for 24 hours washed and cultured for additional 24 hours in the absence of cytarabine.
Cells were harvested, stained with a-Gr1-PE antibody and subjected to FACS analysis. Shown is a representative experiment. (C) Ras cells show
decreased expression of stem cell factor kit. Control and Ras cells were cultured as before and RQ-PCR was performed. The asterisk represents
statistical significance of differences between control- and Ras cells at the indicated time points. (D) The Atm/r-kinase inhibitor caffeine abrogates the
cytarabine-induced differentiation in Ras cells. Control and Ras cells were treated with either 100 nM cytarabine or 0.5 mM caffeine, respectively, or
with both components simultaneously for 24 hours, washed and cultured for additional 48 hours in the absence of cytarabine. Cells were harvested,
stained with a-Gr1-PE antibodies and subjected to FACS analysis. Shown is a representative experiment. (E) Primary AML cases with oncogenic N-RAS
mutations reveal a higher expression of the myeloid differentiation marker SIAT10 upon RQ-PCR analysis. 12 cases with (group 1), and 19 cases
without (group 2) oncogenic N-RAS mutations were analyzed for SIAT10 expression relative to HL60 cells. Shown are the individual samples and the
mean expression (p=0.04).
doi:10.1371/journal.pone.0007768.g005
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Ink4a-resistant Cdk4R24C does not
abrogate myeloid differentiation
Relative to control cells, Ras cells express elevated levels of
p16
Ink4a (Figure 3A), which inhibits Cdk4 kinase activity, leading to
activation of the retinoblastoma tumour suppressor protein (Rb). In
addition, they express elevated levels of p19
Arf and show enhanced
checkpoint activity, both leading to activation of p53. To identify
which if any of these two proteins is a critical downstream effector of
Ras that mediates the cytarabine-induced loss of clonogenicity, we
generated Ras cells that express either Cdk4R24C, a melanoma-
derived mutant of Cdk4 that is resistant to inhibition by p16
Ink4a
[37] or a dominant-negative allele of p53 [38].
Immunoblots revealed that Cdk4R24C was expressed in Ras
cells and had no effect on the activation of Chk1 in response to
treatment with cytarabine (Figure S9A); furthermore, expression of
Cdk4R24C led to elevated levels of phosphorylated pRb,
consistent with its ability to negate the effect of p16
Ink4a (Figure
S9B). Importantly, expression of Cdk4R24C had no effect of the
cytarabine-induced differentiation of Ras cells (Figures S9C,D,E)
and further suppressed their clonogenic potential in the presence
of cytarabine (Figure S9F), strongly suggesting that p16
Ink4a is not
a critical mediator of Ras action in this setting.
Dominant negative p53 inhibits oncogenic RAS- and
cytarabine-induced differentiation
To test whether the observed differentiation depends on p53, we
expressed a dominant negative allele of p53 (p53DD) in Ras cells
(generating Ras/p53DD cells) [38]. Immunoblots confirmed the
expression of p53DD in these cells, and showed that cytarabine-
inducedphosphorylationofChk1isindependent ofp53 (Figure 6A).
In contrast, expression of p53DD abrogated cytarabine-induced
p21
Cip1 expression, a downstream target of p53; furthermore levels
of endogenous p53 were elevated in cells expressing p53DD,
indicative of downregulation of the MDM2 gene (Figure 6B and
Figure S10). These data demonstrate that p53DD blocked p53
function in Ras cells.
Importantly, May-Grunwald-Giemsa staining showed that un-
treated Ras/p53DD cells had an immature phenotype in contrast to
Ras cells, which showed a monocytic/macrophage like morphology
(Figure 6C). RQ-PCR analysis showed that expression of p53DD
decreased the basal expression of ly6g and itgam mRNAs and
abrogated the cytarabine-induced increase in expression of these
markers of myeloid differentiation (Figure 6D); very similar results
were obtained in a FACS analysis of Gr1 and Mac1 protein
expression (Figure 6E; Figure S11). In order to analyse whether the
Ras-induced inhibition of colony growth was also mediated by p53,
Ras/p53DD cells were analysed in the colony test after pre-
treatment with cytarabine as before. Importantly, expression of
p53DD, but not the inactive L344P mutant of p53DD, restored the
clonogenic potential of Ras cells upon transient exposure to
cytarabine (Figure 6F and Figure S12). Similar results were
obtained by inhibition of p53 with the small molecule pifithrin-a
[39] (Figure S12).
Taken together these data strongly suggest that the loss of
clonogenicity and increased differentiation observed in Ras cells in
response to cytarabine is mediated by activation of p53.
Nutlin-3 enhances the biological effects induced by
oncogenic RAS and cytarabine
As shown above, p53 is needed for the cytarabine and
oncogenic RAS driven myeloid differentiation program in
leukemia cells. Nutlin-3 activates endogenous p53, as it inhibits
the Mdm2-induced degradation of p53 [40]. Nutlin-3 can induce
p53-dependent apoptosis in acute leukemia cells [41–43]. Interest-
ingly, a nutlin-dependent maturation program has recently been
described in AML cells [44]. We therefore wanted to know
whether incubation of Ras cells with cytarabine together with
nutlin-3 lead to increased myeloid differentiation in these cells.
To address whether the biological effects of endogenous p53
could be enhanced using nutlin-3, we measured the expression of
p21
Cip1 as a downstream effector of p53. Expectedly, expression of
p21
Cip1 increased after incubation of Ras cells with cytarabine
(Figure 7A). Nutlin-3 incubation also induced, to a lesser degree,
p21
Cip1 expression. Importantly, co-incubation of nutlin-3 togeth-
er with cytarabine potentiated cytarabine-induced p21
Cip1 expres-
sion in Ras cells (Figure 7A); in contrast, neither cytarabine nor
nutlin-3 had any effect on p21
Cip1 expression in Ras/p53DD cells.
We next asked whether nutlin-3 was also able to enhance
cellular differentiation in Ras cells. RQ-PCR analysis showed that
expression of differentiation marker genes ly6g and itgam was
significantly increased when Ras cells were co-incubated with
nutlin-3 and cytarabine (Figures 7B,C). Moreover, nutlin-3 was
unable to stimulate differentiation of Ras/p53DD cells, demon-
strating that it does not act via a p53-independent mechanism.
Together, the data show that Mdm2-mediated degradation of p53
limits the differentiation observed in response to cytarabine and
that combination of nutlin-3 enhances the differentiation-inducing
effect of cytarabine.
Finally, we noted that withdrawal of 4-hydroxy-tamoxifen to
switch off the MLL-ENL-ER chimera induced expression of ly6g
and itgam in control and in Ras cells, but was unable to do so in
Ras/p53DD cells (Figure 7D), arguing that p53 is essential for
granulocytic and monocytic differentiation, at least in the context
of oncogenic Ras.
Discussion
Oncogenic RAS mutations are among the most frequent
mutations observed in human cancers (reviewed in [6]). Until
recently, the prognostic role of oncogenic RAS in AML was not
well understood. Some studies reported a correlation with poor
outcome [45–47], whereas others observed a better prognosis in
AML with oncogenic RAS mutations [48–50]. We have recently
extended these analyses and have demonstrated an interaction
between oncogenic RAS and the dose of cytarabine used during
postinduction-treatment with respect to the cumulative incidence
of relapse and overall survival [26]. Patients, whose AML blasts
revealed oncogenic RAS mutations and who had been treated with
low-dose cytarabine, had the worst prognosis (highest incidence of
relapse; worst survival) [26]. In contrast, those with oncogenic RAS
randomly treated with high-dose cytarabine had the best prognosis
of all groups (lowest incidence of relapse, best survival). Patients
with wild type RAS had only little benefit from cytarabine dose-
escalation, and their prognosis was in between the patients with
RAS mutations. The molecular basis for this observation remained
unclear.
In order to molecularly understand the interaction of oncogenic
RAS with cytarabine in AML, we took advantage of mouse bone
marrow cells that had been immortalized using a conditional MLL-
ENL-ER oncogene [27,28] and that were co-infected with either an
empty vector (control cells) or a vector expressing oncogenic RAS
(Rascells). Wechose leukemiccells expressing MLL-ENLforseveral
reasons: first, MLL-ENL is a potent oncogene and is able to
transform and immortalize progenitor cells at various levels of
myeloid differentiation, although high-doses of growth factors are
still needed for in vitro culture, most likely to substitute for a lack-
ing class I mutation in these cells [27,51]. Second, MLL-ENL
RAS and Cytarabine in AML
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7768Figure 6. p53 is required for RAS- and cytarabine-induced suppression of clonogenicity. (A) Phosphorylation of Chk1 is independent of
functional p53. Ras and Ras/p53DD cells, expressing dominant negative p53, were treated with 100 mM cytarabine for one hour. The panels show
immunoblots probed with the indicated antibodies. (B) Cytarabine-induced expression of p21
Cip1 is abrogated by p53DD. Ras and Ras/p53DD cells
were incubated with 350nM cytarabine for 24 hours. Immunoblots of cell lysates were probed with antibodies against p53, p53DD, p21
Cip1 and Cdk2.
(C) p53DD induces a blast-like morphology in Ras cells. Cells were stained with May-Grunwald/Giemsa and pictures were taken as described before.
(D) p53DD suppresses expression of ly6g and itgam mRNA in Ras cells. Ras and Ras/p53DD cells were treated with 350 nM cytarabine for 24 hours
and RQ-PCR was performed as before. The double asterisk represents statistical significance of differences between Ras cells and Ras/p53DD cells
(p,0.01). (E) Expression of Gr1 proteins is suppressed by p53DD. Ras and Ras/p53DD cells were treated with 350 nM cytarabine for 24 hours and
subsequently cultured for additional two days in the absence of cytarabine. Cells were subjected to FACS analysis using a2Gr1-PE antibodies. (F)
Expression of p53DD enhances the colony formation potential of Ras cells upon cytarabine treatment. The assay was performed as described in
Figure 2.
doi:10.1371/journal.pone.0007768.g006
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lation resembling acute myeloid leukemia in humans [52]; third,
once MLL-ENL-ER is switched off, the cells differentiate and
undergo apoptosis, demonstrating the importance of this fusion
gene for maintaining self renewal and growth.
Although in vivo therapy with cytarabine underlies a complex
pharmacodynamic and pharmacokinetic regulation which may
not be reproduced in the cell culture system used in this study [53],
the MLL-ENL cells showed phenomena in vitro which resemble the
observations made in the clinical study [26]. Notably, there was no
significant difference between the cell number, cell survival or
apoptosis of Ras and control cells treated with cytarabine. This
corresponds with the clinical situation where a significant
difference between AML-patients with and without RAS mutations
with regard to complete remission was not found. Instead, the
clinical observation that patients with oncogenic RAS relapse less
frequently after complete remission suggested that the number of
clonogenic stem cells able to cause AML relapse may be
significantly decreased in AML with oncogenic RAS mutations
upon treatment [26]. This may correlate with the lower in vitro
clonogenicity of Ras cells that have been transiently exposed to
cytarabine (and, as shown in Figure 4, to other cytotoxic drugs
such as daunorubicine and etoposide).
Our analysis provides several molecular correlates for these
observations and suggests that the difference in response to
cytarabine is due to known biological properties of oncogenic RAS.
Notably, Ras is known to activate expression of several proteins
associated with cellular senescence, such as p16
Ink4a, p19
Arf and
p21
Cip1 [20] and we confirmed these observations for the leukemic
cells studied here (Figure 3A). Oncogenic RAS also activates a
DNA damage response in primary fibroblasts [24,25,54]. While
oncogenic RAS was unable to induce a DNA-damage response in
MLL-ENL cells by itself, it strongly enhanced the DNA-damage
response observed after incubation with DNA-damaging agents
such as cytarabine. As a result, high levels of p53 are present in Ras
cells treated with cytarabine (Figure 3B) and mediate their loss of
clonogenicity (Figure 6F).
Oncogenic RAS synergizes with cytarabine to enhance
differentiation of AML cells
Activated DNA damage checkpoint frequently induce cell cycle
arrest or apoptosis, yet we have not observed any difference in
regard to apoptosis or proliferation after cytarabine treatment
between Ras and control cells. It has been reported that cytarabine
can induce myeloid differentiation (e.g. [33,55]). Numerous studies
have also shown that oncogenic RAS also induces differentiation
Figure 7. Nutlin-3 enhances the biological effects of oncogenic RAS in a p53-dependent manner. (A) Nutlin-3 and cytarabine co-operate
to induce p21
Cip1 expression in Ras cells but not in Ras/p53DD cells. Cells were treated for 24 hours with either 350 nM cytarabine (A) or nutlin-3 (N)
alone or simultaneously (A+N) as indicated. The immunoblots show the expression of p53, p21
Cip1 and p53DD in the indicated cell types. (B, C)
p53DD abrogates the nutlin- and cytarabine-induced expression of ly6g (B) and itgam (C) mRNAs. Ras- and Ras/p53DD-cells were treated for 24 hours
with either 350 nM cytarabine or nutlin-3 alone or simultaneously as indicated and RQ-PCR was performed. The double asterisk indicates a significant
difference between Ras cell untreated and treated with cytarabine and nutlin-3 and between Ras cells and Ras/p53DD cells in the presence of
cytarabine and nutlin (p,0.01). (D) Differentiation of Ras cells due to withdrawal of 4-OHT is blocked by p53DD. Control, Ras and Ras/p53DD-cells
were cultured for 12 days in the presence or absence of 4-OHT and the expression of ly6g mRNA was analysed by RQ-PCR. The double asterisk
represents statistical significance (p,0.01) of differences between control cells and Ras cells cultured in the presence of 4-OHT as well as differences
between Ras cells and Ras/p53DD cells cultured in the presence and absence of 4-OHT, respectively.
doi:10.1371/journal.pone.0007768.g007
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tiation in control cells, when treated with cytarabine. This was
significantly increased in Ras cells incubated with cytarabine
(Figure 5). Therefore, either molecular change alone was ineffec-
tive in inducing full differentiation, whereas the combination of
both did. Notably, the increased differentiation was abolished
by incubation with caffeine, an inhibitor of the Atm and Atr
kinases, demonstrating that it depends on checkpoint activation
(Figure 5D). Taken together, the data suggest that oncogenic RAS
in combination with higher doses of cytarabine induces differen-
tiation in vitro and strongly decreases the clonogenic potential.
Supporting this notion, Ras cells treated with cytarabine were
much less likely to express the stem cell marker kit as compared to
control cells (Figure 5C). Also, primary AML cells with oncogenic
N-RAS mutations revealed a higher expression of differentia-
tion markers as compared to patients lacking such mutations
(Figure 5E).
Oncogenic RAS- and cytarabine-induced myeloid
differentiation depends on p53
TP53 is frequently mutated in human cancer, but rarely in
myeloid leukemias; therefore, the MLL-ENL transformed cells here
mimic the p53 status found in AML. Importantly, our data identify
p53 as a critical mediator of the enhanced differentiation and loss of
clonogenicity observed in Ras cells upon exposure to cytarabine.
This was supported by the observation that Ras cells expressing
p53DD did not undergo differentiation upon treatment with
cytarabine (Figures 6D,E). Also, treatment of Ras cells with both
cytarabine and nutlin-3, an inhibitor of Mdm-2 induced degrada-
tion of p53, caused a further increase in p21
Cip1 expression, which
was paralleled by increased expression of differentiation markers
(Figures 7A,B,C) and is consistent with a recent report that nutlin-3
can cause maturation in AML cells [44].
Notably, Ras cells expressing p53DD did not differentiate even
when the MLL-ENL-ER oncogene was switched off by withdraw-
ing 4-hydroxy-tamoxifen (Figure 7D), demonstrating that p53 is
required for induction of differentiation of these cells. MLL-ENL
has been shown to attenuate p53 function, since it antagonizes the
interaction of p53 with the p300/CBP co-activator [56]; it is
conceivable that this activity of MLL-ENL counteracts the
induction of differentiation by low levels of active p53, such as
might be present in cells expressing oncogenic RAS in the absence
of cytarabine.
One caveat in our study is the use of H-Ras, while AML patients
more frequently harbor mutations in the N-RAS or K-RAS genes
[48]. However, the signaling pathways downstream of Ras
proteins are conserved and H-Ras can substitute for K-Ras during
embryonic development [57]. Furthermore, higher expression of
differentiation markers in primary AML cells with oncogenic
N-RAS mutations (Figure 5E) strongly suggests that mutant H-Ras
and N-Ras function similarly to promote differentiation in hema-
topoietic cells.
Our findings may have implications for understanding how
chemotherapeutic drugs exert their effects. Conventionally,
cytostatic drugs such as cytarabine are thought to act as inhibitors
of proliferation and inducers of apoptosis. This study suggests that
the critical function of a cytotoxic drug such as cytarabine may be
to promote the differentiation of tumor-initiating cells. That
induction of differentiation is an attractive goal for anticancer
therapy and is associated with higher cure rates has been
demonstrated elegantly in acute promyelocytic leukemia, where
high-doses of retinoic acid, given concomitantly with chemother-
apy, overcomes the repressive effect of PML-RARa in differen-
tiation. We propose that induction of differentiation should
therefore be seen as a broader goal in AML therapy, e.g. for in
vitro screening of new compounds, and in the development of new
treatment protocols. The success of such a procedure will depend
on the genetic background of the respective cancer cells.
Materials and Methods
Retroviral transduction of mouse primary hematopoietic
cells
High-titer retrovirus supernatants were produced by transient
transfection of the packaging cell line Phoenix-E using a standard
Ca
2+-phosphate precipitation method. Viral titers usually reached
approximately 5610
6 CFU/ml. Retroviral transduction of pri-
mary hematopoietic cells was performed as described previously
[58]. All constructs (Ha-RasV12, Cdk4R24C-Flag, p53DD (aa
302–390), p53LP (p53DD with L344P mutation) were cloned into
pMSCV retroviral vectors (Clontech, USA) and cells were
cultured in the presence of either puromycin, hygromycin or
blasticidin, respectively. In total, we performed three independent
infections of MLL-ENL cells with either control viruses or viruses
encoding oncogenic RAS, using two different clones of MLL-ENL
cells. The results we obtained were consistent between these
independent experiments.
Tissue culture and growth assays
Transduced bone marrow cells were kept either in MethoCult
(M3234) methylcellulose medium (Cell systems, St. Katharinen,
Germany) or in RPMI 1640 (Gibco, Karlsruhe, Germany). Recom-
binant mouse cytokines (Cell Systems, St. Katharinen, Germany)
were added in the following concentrations: interleukin-3, inter-
leukin-6, and granulocyte-macrophage colony-stimulating factor
(GM-CSF), 10 ng/ml; SCF, 100 ng/ml. All liquid media were
supplemented with 10% bovine fetal calf serum (Gibco, Karlsruhe,
Germany) and penicillin-streptomycin. 4-Hydroxy-tamoxifen (4-
OHT) was added to a final concentration of 100 nM from a 1 mM
stock solution in ethanol.
To measure checkpoint responses in short-term assays, cells were
treated either with up to 100 mM cytarabine (Merck, Darmstadt,
Germany) for the indicated times or exposed to UV-B for 3.5 min
and subsequently cultured at 37uC. Where indicated, cells were co-
treated with 500 mM caffeine (Sigma Aldrich, Munich, Germany).
For long-term assays, cells were exposed to 100 nM cytarabine
unless indicated otherwise. For stabilization of p53 protein, Nutlin-3
(SigmaAldrich, Munich, Germany) wasadded at a concentrationof
5 mM. For inhibition of p53 protein cells were treated with 20 mM
Pifithrin-a (Calbiochem, Gibbstown, NJ, USA).
For immunoblot analysis of phopho-Chk1, cells were exposed for
1ht o1mM, 10 mMa n d5 0 mM daunorubicine (Pfizer, Berlin,
Germany) and etoposide (Teva-Gry, Kirchzarten, Germany), respec-
tively. Colony formation assays were performed with concentrations
of 10 nM and 25 nM for daunorubicine and 50 nM and 250 nM for
etoposide.
Colony formation
The assays were performed in methylcellulose medium and
colonies were stained with INT (Iodonitrotetrazolium chloride,
Fluka, Buchs, Switzerland) at a final concentration of 1 mg/ml.
For cell counting, methylcellulose was diluted in PBS, cells
harvested and live cells were counted in triplicates of each sample
using exclusion of trypan blue as criterion. Pictures of the colonies
were captured using a Leica MZ125 binocular together with Leica
DC300 camera and Leica IM1000 software (Leica Microsystems,
Switzerland).
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Cells were assayed for the senescence-associated b-galactosidase
activity by x-gal staining as described in [59] and subsequently
transferred to slides by cytocentrifugation. Pictures were taken by
Leica DMLB microscope with a Leica DFC420 camera and Leica
DFC Twain software (Leica Microsystems, Switzerland).
Morphological analysis
A cytocentrifuge was used to spin cells onto slides. Staining was
performed using May-Grunwald and Giemsa (Sigma Aldrich,
Munich, Germany) according to the manufacturers protocol.
Immunofluorescence
Samples were fixed in 3,7% paraformaldehyde for 10 min,
followed by permeabilization in PBS-T (PBS containing 0.2%
Triton X-100). Nonspecific protein binding was blocked by 5%
FCS (Gibco, Karlsruhe, Germany). Cells were stained using a
primary antibody against phospho-Atm (pSer1981, Chemicon,
USA) and a FITC-conjugated a-rabbit in parallel to Hoechst.
Pictures were taken by BD Pathway 855 High-Content Bioimager
with BD AttoVision 1.6 software (BD Biosciences, Heidelberg,
Germany).
Immunoblot and antibodies
Cells were lysed either in TNN buffer (50 mM Tris, pH 7.4,
150 mM NaCl, 0.5% NP-40, 5 mM EDTA, 1 mMDTT, protease
and phosphatase inhibitors (Sigma Aldrich, Munich, Germany),
Ripa buffer (10 mM NaPO4, pH 7.2, 150 mM NaCl, 1% NP-40,
0.1% Sodium Deoxycholate, 0.1% SDS) or NP-40-Lysisbuffer
(50 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, pH 8.0). Proteins
were separated by SDS gel electrophoresis and transferred to
Immobilon-P (Millipore, CA, USA). Proteins were detected by
immunoblotting. Antibodies used were phospho-Erk (pTyr204),
Cdk2, p53, p21
Cip1,p 1 6
Ink4a, Chk1, phospho-Rb (pSer795), Rb (all:
Santa Cruz Biotechnology, Heidelberg, Germany), Ras (BD
Transduction Laboratories), p19
Arf (Abcam, Cambridge, UK),
phospho-Chk1 (pSer345), phospho-H2a.x (pSer139) (both: Cell
signaling, USA) and phospho-Atm (pSer1981) (Chemicon, USA),
p53DD (monoclonal mouse antibody pAb122) and Flag-antibody
(Sigma Aldrich, Munich, Germany).
Ras pull-down assay
The activity of Ras was analyzed with Ras Activation Assay Kit
from Millipore (CA, USA) according to the manufacturers
recommendations. Lysates of 6610
6 cells were used for the Ras
pull-down assay.
Flow cytometric analysis
Antibodies for flow cytometric (FACS) analysis (isotype control,
Gr-1/Ly6G/C, Mac-1/CD11b) were purchased from BD Biosci-
ences (Heidelberg, Germany) and used according to the recom-
mendations of the manufacturer. The histograms display the
geometric mean (GeoMean) of the analysed sample. The BrdU-
FACS was carried out with the FITC BrdU Flow Kit (BD
Pharmingen, BD Biosciences, Heidelberg, Germany) according to
the manufacturers instructions.
The separation of cells positive and negative for Mac1 and c-kit,
respectively was performed via the MACS-system (Miltenyi,
Bergisch-Gladbach, Germany). The separation was carried out
using anti-PE microbeads and MS columns in combination with
Mac-1/CD11b-PE and c-kit/CD117-PE antibodies from BD
Biosciences (Heidelberg, Germany) according to the instructions
of the manufacturer.
RQ–PCR and RT-PCR
RNA was isolated with PeqGold TriFast according to the
manufacturers instructions (Peqlab, Erlangen, Germany). RNA
(2 mg) was reverse transcribed with 200 U M-MLV-RT (Invitro-
gen, Karlsruhe, Germany). cDNA was amplified either by PCR
using a Q-PCR kit (Immomix from Bioline, Luckenwalde,
Germany) and the product detected on agarose gel, or by
quantitative real-time PCR and the product detected with SYBR
green using a Mx3000 (Stratagene, USA) detection system.
Expression of rps16 mRNA was used as reference. Real-time
PCR was performed in triplicates and error bars indicate standard
deviation. 31 primary AML cases with inversion (16), diagnosed
and treated within the Germany AML-SHG 96 trial, were
provided by T.I. and analyzed by RQ-PCR for SIAT10
expression. Expression values were normalized to b-actin mRNA
and HL60 cells as a reference.
Mutagenesis PCR
The mutagenesis of mutated RasV12 to wild type Ras was done
with Quick Change Multi Site-Directed Mutagenesis Kit from
Stratagene (CA, USA) according to the protocol of the
manufacturer. The sequences of primers used for the PCR
reaction were as follows: forward primer, GTTGTTGTTGG-
CGCCGGTGGTGTGGGCAAGAGTG, reverse primer, CAC-
TCTTGCCCACACCACCGGCGCCAACAACAAC.
Statistical analysis
Statistical analysis was performed with two-tailed Student’s t test
with Welch’s correction.
Supporting Information
Figure S1 RAS does not influence the expression of MLL-ENL-
ER. (A) Total RNA was isolated from control and Ras cells and
after cDNA synthesis PCR with primers specific for MLL-ENL-
ER was performed. Samples were analysed on an agarose gel. RT,
reverse transcriptase. rps16: control gene
Found at: doi:10.1371/journal.pone.0007768.s001 (0.23 MB TIF)
Figure S2 Ras cells show enhanced sensitivity to cytarabine in
clonogenic assays. (A) Quantification of the colony assays shown
in Figure 2E. Triplicate samples of cells incubated for 24 hours
with the indicated concentrations of cytarabine were plated in
methylcellulose; colonies were stained after 4 days. The plot shows
the relative efficiency of colony formation of Ras versus control
cells. To generate this plot, the average number of colonies formed
by control cells at each concentration of cytarabine was arbitrarily
set to one. (B) Reprensentative colony assays of two independently
derived clones of MLL-ENL cells and their corresponding Ras
cells treated for 24 hours with the indicated concentrations of
cytarabine.
Found at: doi:10.1371/journal.pone.0007768.s002 (1.53 MB TIF)
Figure S3 Control- and Ras cells consist of different populations.
(A) Sorting of Mac1-positive vs Mac1-negative cells. The table
shows the number of cells after Mac1 separation. The bulk
population of control and Ras cells consist mainly of undifferen-
tiated, Mac1-negative cells. (B) Sorting of c-kit-positive vs c-kit-
negative cells. The table shows the number of cells after c-kit
MACS separation. (C) 3.000 MACS separated control and Ras
cells were plated in methylcellulose and colonies were stained after
four days. The graph shows the number of colonies observed in
three independent colony formation assays of MACS sorted cells.
Found at: doi:10.1371/journal.pone.0007768.s003 (0.36 MB TIF)
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marginal activation of the checkpoint after cytarabine treatment.
(A) MLL-ENL-ER cells were infected with retroviruses expressing
wild type HA-RAS. Two different pools of infected cells (wt1 and
wt2) expressing different levels of wild type HA-RAS were treated
with 50 mM cytarabine for one hour and the immunoblots probed
with the indicated antibodies. (B) RQ-PCR analysis documenting
the relative mRNA expression levels of either wild type HA-RAS
(wt) or oncogenic (Ras) HA-RAS.
Found at: doi:10.1371/journal.pone.0007768.s004 (0.62 MB TIF)
Figure S5 Dependence of Chk1-phosphorylation and of colony
formation of control and Ras cells on the concentration of
cytarabine. (A) Quantification of the immunoblot shown in
Figure 4A. (B) Quantification of the colony assays shown in
Figure 4B. This plot shows the relative efficiency of colony
formation of Ras versus control cells. To generate this plot, the
average number of colonies formed by control cells at each
concentration of cytarabine was arbitrarily set to one.
Found at: doi:10.1371/journal.pone.0007768.s005 (0.58 MB TIF)
Figure S6 Enhanced differentiation of Ras cells in response to
cytarabine. (A) Quantification of the morphological analysis shown
in Figure 5A. Meta, Metamyelocyte; PMN, polymorphonuclear;
Mono, Monocyte; Macro, Macrophage. (B) Control and Ras cells
untreated or treated with 350 nM cytarabine for 24 hours were
stained with PE-labeled antibodies against Mac1 and Gr1,
respectively, and subjected to FACS analysis.
Found at: doi:10.1371/journal.pone.0007768.s006 (0.92 MB TIF)
Figure S7 Caffeine abrogates the phosphorylation of Chk1. (A)
The panel shows an immunoblot of Ras cells treated with 100 mM
cytarabine for one hour in the presence of the indicated
concentrations of caffeine; the blot was probed with antibodies
against phospho-Chk1 (pSer345). (B) Immunoblots of Ras cells
treated with 100 mM cytarabine for eight hours in the presence of
the indicated concentrations of caffeine; the blot was probed with
antibodies against p53 and p21.
Found at: doi:10.1371/journal.pone.0007768.s007 (0.40 MB TIF)
Figure S8 Phosphorylation of Chk1 is independent of differen-
tiation. The panels show immunoblots of lysates from control and
Ras cells, which were cultured 12 days in the absence of 4-OHT.
The indicated cell types were probed with antibodies against
phospho-Chk1 (pSer345) and Cdk2. Cells were treated either with
100 mM cytarabine for the indicated times or with UV-B for 3.5
minutes and subsequently incubated for the indicated times. Exp.
= exposure.
Found at: doi:10.1371/journal.pone.0007768.s008 (0.29 MB TIF)
Figure S9 Expression of Cdk4R24C does not abrogate myeloid
differentiation. (A) Cdk4R24C does not abrogate phosphorylation
of Chk1. Immunoblot documenting the expression of Cdk4R24C,
phospho-Chk1 (Ser345) and Ras. Ras and Ras/Cdk4RC cells
were treated with 100 mM cytarabine for one hour. Cell lysates
were probed for Cdk4R24C-Flag with antibodies against Flag,
phospho-Chk1 (Ser345), Ras and Cdk2. (B) Phosphorylation of Rb
is elevated in Ras/Cdk4R24C cells. Ras and Ras/Cdk4R24C cells
were incubated with 100 mM cytarabine for the indicated times.
The panels show immunoblots of cell lysates that were probed with
antibodies against phospho-Rb (pSer807 and pSer811), Rb,
p16Ink4a and Flag (Cdk4R24C). Cdk2 served as loading control.
The asterisk denotes a non-specific band. (C) Ras cells differentiate
despite expression of Cdk4R24C. Ras and Ras/Cdk4R24C cells
were treated with 350 nM cytarabine for 24 hours, washed and
cultured for additional two days in the absence of cytarabine. Cells
were subjected to FACS analysis using a-Gr1-PE antibodies. (D)
Quantification of (C). (E) Cytarabine induces the expression of
ly6g mRNA in Ras/Cdk4R24C. Ras and Ras/Cdk4R24C cells
were treated with 350 nM cytarabine for 24 hours and expression
of ly6g mRNA was analyzed by RQ-PCR. (F) Cdk4R24C does not
enhance the clonogenic potential of Ras cells. The assay was
performed as described in Figure 2.
Found at: doi:10.1371/journal.pone.0007768.s009 (0.81 MB TIF)
Figure S10 Expression of mdm2 is downregulated in Ras/
p53DD cells. Ras and Ras/p53DD cells were treated with 350 nM
cytarabine for 24 hours and expression of mdm2 mRNA was
analyzed by RQ-PCR.
Found at: doi:10.1371/journal.pone.0007768.s010 (0.20 MB TIF)
Figure S11 p53 is required for RAS- and cytarabine-induced
differentiation. Ras and Ras/p53DD cells were treated with
350 nM cytarabine for 24 hours washed and cultured for
additional two days in the absence of cytarabine. Cells were
subjected to FACS analysis using a-Gr1-PE and a-Mac1-FITC
antibodies, respectively.
Found at: doi:10.1371/journal.pone.0007768.s011 (0.22 MB TIF)
Figure S12 Inhibition of p53 by pifithrin-a enhances the colony
formation potential of Ras cells upon cytarabine treatment.(A)
Cells were treated for 24 hours with 100 nM cytarabine and
20 mM pifithrin-a as indicated. Samples of 3.000 cells each were
plated in methylcellulose. Colonies were stained after four days.
Expression of the inactive L344P mutant of p53DD (p53LP) does
not restore the clonogenic potential of Ras cells upon transient
exposure to cytarabine. (B) Quantification of (A). The graph shows
the number of colonies relative to the number of colonies observed
in the absence of cytarabine. The graph shows the average of three
independent experiments.
Found at: doi:10.1371/journal.pone.0007768.s012 (1.23 MB TIF)
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